Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorCity of Hope Medical Center
About this trial
The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.
Eligibility criteria
Qualifiers
Patients who had histologically confirmed ESCC.
Patients who had undergone only complete esophagectomy with radical lymph node dissection without chemotherapy or radiotherapy before or after surgery.
Patients for whom tissue samples are available
Patients who were followed-up completely, with information on observation periods of at least 2 years after surgery.
Disqualifiers
Patients lacking clinical information within 2 years of surgery.
Patients with multiple cancers.
Trial design
Treatments tested in this trial
- Surgery
Treatment groups
150 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov